Products and services

Contact and locations

Activery The amorphization specialist

Activery The amorphization specialist

Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics

Service analyse DSC

SERVICE ANALYSE DSC ET TGA Activery offre aussi le service d analyse thermique (analyse DSC et TGA) en externalisation. Nous effectuons l analyse thermique pour différents produits chimies, polymères, cosmétiques et , spécialement, pour produits pharmaceutiques come des principes actives ou for...

Creating new paths to differentiated medicines

Creating new paths to differentiated medicines

In Activery we believe that solid state modifications may lead to a critical changes in your active pharmaceutical, thus to a differentiated drug or to a brand new innovative medicine  

Activery, the solid state specialist

Activery, the solid state specialist

Activery possess unrivalled specialist expertise about different crystallization techniques and expert knowledge in the field of solid state modulation.  

Particles and nanoparticles for special uses

Particles and nanoparticles for special uses

In Activery, we design and produce particles for special uses where size matters such as nanoparticles for cancer treatment. Through our technology you would enable new administration routes or renewed performance of your drug formulation.  

Increased Competition, Generic Erosion and Cost Consciousness Will Cause Asthma Drug Market to Decline to $10.1 Billion in 2017 PDF Print E-mail

Increased Competition, Generic Erosion and Cost Consciousness Will Cause Asthma Drug Market to Decline to $10.1 Billion in 2017


However, Launch of New Agents Will Drive Growth in the Long-Acting Beta- Agonist/Inhaled Corticosteroid Class, According to a New Report from Decision Resources

WALTHAM, Mass., May 19, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that increased product competition, generic and/or branded- generic price erosion, and cost consciousness will constrain growth in the asthma drug market as sales will decline from $10.9 billion in 2007 to $10.1 billion in 2017 in the world's major pharmaceutical markets.



The new Pharmacor report entitled Asthma finds that although sales will decline over the next decade in the United States, France, Germany, Italy, Spain, United Kingdom and Japan, the launch of several new long-acting beta- agonist/inhaled corticosteroid (LABA/ICS) combinations will drive growth in this class. However, none of five new LABA/ICS therapies that are set to launch by 2017 will overtake the current market leader in this class- GlaxoSmithKline's Advair/Seretide/Adoair, owing to its well-established patient share.

The report also finds that although the asthma market is saturated with many safe and effective drugs, pharmaceutical companies continue to develop new therapies to maximize their earning potential in this lucrative market.

"Asthma therapies that are emerging over the next ten years in the U.S., European, and/or Japanese markets that offer improved convenience will capture market share but will still not surpass sales of Advair/Seretide/Adoair," said Amy Whiting, Ph.D. analyst at Decision Resources. "Other key players will rely on competitive pricing, incremental gains in safety, or improved efficacy to differentiate themselves from competitors."